Table 2.
Patient and tumor characteristics of eligible studies
| Author | Sample | Age | Male | Treatment | Type of Neck Dissection | T stage | N stage | Subsite | LNY | PN+ |
|---|---|---|---|---|---|---|---|---|---|---|
| Ye [22] | 93 | Mean 56.9 (32 to 87) | 98% | Surgery OR Surgery with (RT OR CRT) | Radical, Elective | T1 to T4 | N0, N1, N2a/b/c, N3 | Pyriform sinus, Posterior wall, Postcricoid region, | NA | Mean 3 (0 to 34) |
| Lo [15] | 120 | Mean 56 (35 to 89) | 98% | Surgery OR Surgery with (RT OR CRT) | Bilateral, Unilateral | T1 to T4 | N0, N1, N2a/b/c, N3 | Pyriform sinus, Posterior pharyngeal wall, Postcricoid | NA | Mean 4 |
| Suzuki [21] | 46 | Median 66 | 94% | Surgery OR Surgery with (RT OR CT OR CRT) | Extended radical, Modified Radical, Selective | T1 to T4 | N1, N2 | Priform sinus, Others | Median 59.5 (14 to 114) | Median 3 (1 to 15) |
| Joo [14] | 105 | Mean 61 (35 to 80) | 97% | Surgery OR Surgery with (RT OR CRT) | Bilateral, Modified Radical, Radical, Selective | T1 to T4 | N1 to N3 | Pyriform sinus, Posterior pharyngeal wall, Postcricoid region | Median 54 (15 to 176) | Median 3 (1 to 31) |
| Hua [13] | 81 | Median 60 (36 to 80) | 98% | Surgery OR Surgery with (RT OR CRT) | Bilateral, Unilateral | T1 to T4 | N1 to N3 | Pyriform sinus, Posterior wall, Postcricoid region | Median 47 (3 to 95) | Median 2 (0 to 17) |
| Yu [29] | 279 | Mean 57.8 (34 to 85) | 93% | RT OR RT with (CRT OR ICT OR Surgery OR Surgery with CT) | Radical, Modified Radical, Selective | T1 to T4 | N0 to N3 | Pyriform sinus, Posterior wall, Postcricoid region | Median 20 (2 to 76) | Median 2.0 (0.5 to 22.0) |
| Wang [27] | 916 | Median 61 (35 to 93) | 42% | Surgery OR Surgery with RT | NA | T1 to T4a/b, Tx | N1 to N3 | Pyriform sinus, Posterior wall, Postcricoid region, Aryepiglottic fold, Overlapping lesion, Hypopharynx | Median 25 (1 to 90) | Median 2 (1 to 90) |
| Imre [19] | 101 | Mean 58.5 (41 to 79) | 95% | Surgery OR Surgery with (RT OR CRT) | Radical, Modified Radical, Selective | T1 to T4 | N1, N2a/b/c | Glottis, Supraglottis, Transglottis | Mean 41.8 (18 to 88) | Mean 2.9 (1 to 15) |
| Ryu [16] | 71 | Median 65 (35 to 79) | 93% | Surgery OR Surgery with (RT OR CRT) | Bilateral, Modified Radical, Radical, Selective | T1 to T4 | N0 to N2 | Supraglottis, Glottis, Transglottis | Median 52 (11 to 153), | Median 4 (1 to 21) |
| Wang [28] | 1963 | NA | 78% |
Surgery OR Surgery with RT |
NA | T1 to T4a/b, Tx | N1 to N3 | Glottis, Supraglottis, Subglottis, Laryngeal cartilage, Overlapping lesion, Larynx | Median 28 (1 to 90) | Median 2 (1 to 90) |
| Künzel [20] | 202 | Median 59 (36 to 86) | 93.1% | Surgery OR Surgery with (RT OR CRT) | Unilateral or bilateral modified radical | T1 to T4 | N1, N2a/b/c | Glottic,Supraglottic,Unspecified site of origin within the larynx | Median 27 (10 to 88) | Median 2 (1 to 19) |
| Choi [12] | 141 | Median 65 (33 to 78) | 93.6% | Surgery OR Surgery with (RT OR CRT) | Radical, Selective | T1 to T5 | N1 to N3 | Larynx, Hypopharynx | Median 60 (11 to 161) | Median 1 (0 to 21) |
| Grasl [18] | 79 | Median 60 (41.6 to 83) | 88.6% | Surgery OR Surgery with (RT OR CRT/IRT) | Radical, Modified Radical, Selective | T1 to T4 | N0, N1, N2a/b/c, N3a/b/c | Larynx, Hypopharynx |
Median ± SD 48.0 ± 23.8 |
NA |
NA Not available, RT Radiotherapy, CT Chemotherapy, CRT Chemoradiotherapy, IRT Radio-immune therapy, LNY Lymph node yield, PN+ Positive lymph node number